date,title,source
Oct-23-18,SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp,PR Newswire
Nov-13-18,"Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates",Zacks
Nov-13-18,Scynexis: 3Q Earnings Snapshot,Associated Press
Nov-13-18,SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update,PR Newswire
